Oncocross Co., Ltd. (KOSDAQ:382150)
South Korea · Delayed Price · Currency is KRW 9,970.00
-150.00 (-1.48%)
Sep 19, 2025, 3:30 PM KST
Oncocross Revenue
Oncocross had revenue of 137.78M KRW in the quarter ending June 30, 2025, a decrease of -20.72%. This brings the company's revenue in the last twelve months to 1.04B, up 280.70% year-over-year. In the year 2024, Oncocross had annual revenue of 1.07B with 1,071.49% growth.
Revenue (ttm)
1.04B
Revenue Growth
+280.70%
P/S Ratio
115.40
Revenue / Employee
33.49M
Employees
31
Market Cap
119.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.07B | 980.68M | 1,071.49% |
| Dec 31, 2023 | 91.52M | -58.72M | -39.08% |
| Dec 31, 2022 | 150.25M | 50.25M | 50.25% |
| Dec 31, 2021 | 100.00M | 10.00M | 11.11% |
| Dec 31, 2020 | 90.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| ABL Bio | 94.93B |